Home Cart Sign in  
Chemical Structure| 106362-34-9 Chemical Structure| 106362-34-9

Structure of DAPTA
CAS No.: 106362-34-9

Chemical Structure| 106362-34-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

DAPTA is a potent and selective CCR5 antagonist.

Synonyms: D-Ala-peptide T-amide; Adaptavir; Monomeric (D-Alanine-1) Peptide T amide

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of DAPTA

CAS No. :106362-34-9
Formula : C35H56N10O15
M.W : 856.88
SMILES Code : OC1=CC=C(C[C@H](NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@H](N)C)=O)CO)=O)=O)[C@H](O)C)=O)=O)CC(N)=O)=O)C(N[C@H](C(N)=O)[C@H](O)C)=O)C=C1
Synonyms :
D-Ala-peptide T-amide; Adaptavir; Monomeric (D-Alanine-1) Peptide T amide
MDL No. :MFCD00076838
InChI Key :AKWRNBWMGFUAMF-ZESMOPTKSA-N
Pubchem ID :184644

Safety of DAPTA

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of DAPTA

GPCR

Isoform Comparison

Biological Activity

Target
  • CCR

    gp120 Bal-CCR5, IC50:0.06 nM

    CM235-CCR5, IC50:0.32 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 cells 0.1 mM 6 hours DAPTA significantly reduced CSE-induced tight junction injury and inhibited the downregulation of ZO-1, occludin, CCL3, and CCR5 expression by CSE. Front Pharmacol. 2021 Apr 19;12:551839.
16-HBE cells 0.1 mM 6 hours DAPTA significantly reduced CSE-induced tight junction injury and inhibited the downregulation of ZO-1, occludin, CCL3, and CCR5 expression by CSE. Front Pharmacol. 2021 Apr 19;12:551839.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SJL/J mice Experimental autoimmune encephalomyelitis (EAE) model Intraperitoneal injection 0.01 mg/kg Once daily from day 14 to day 42 after immunization To evaluate the therapeutic potential of DAPTA in EAE mice, results showed that DAPTA significantly reduced the expression of NF-κB p65, Notch-1, Notch-3, GM-CSF, MCP-1, iNOS, and TNF-α, while increasing the expression of IκBα. Biomedicines. 2023 May 23;11(6):1511
SJL/J mice Experimental autoimmune encephalomyelitis (EAE) model Intraperitoneal injection 0.01 mg/kg Once daily from day 14 to day 42 DAPTA treatment significantly reduced the expression of NF-κB p65, Notch-1, Notch-3, GM-CSF, MCP-1, iNOS, and TNF-α in EAE mice, while increasing the expression of IκBα. Biomedicines. 2023 May 23;11(6):1511
C57BL/6 mice CSE-induced COPD Mice model Subcutaneous injection 10 μg/kg Once daily for 6 weeks DAPTA partially reversed the negative effects of CSE on lung function and tight junction protein expression in mice, reducing alveolar space enlargement and inflammatory responses. Front Pharmacol. 2021 Apr 19;12:551839.
ApoE−/− mice Atherosclerosis model Tail vein injection 370 kBq 1, 4, and 24 hours To evaluate the pharmacokinetics and targeting efficiency of DAPTA-Comb nanoparticles in an atherosclerosis model. Results showed extended blood circulation of 10%, 25%, and 40% DAPTA-Comb, with 40% DAPTA-Comb demonstrating higher plaque targeting efficiency. Mol Pharm. 2021 Mar 1;18(3):1386-1396
Sprague-Dawley rats Conscious adult and juvenile rats Intracerebroventricular (ICV) administration 400 ng (acute), 2 ng (chronic) Acute: single injection; chronic: twice daily for 5 days To investigate the effect of gp120 on GH release and body weight, results showed gp120 significantly suppressed GH release and caused weight loss Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1927-32

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00951743 HIV Infections Phase 2 Unknown July 2010 United States, District of Col... More >>umbia Whitman Walker Clinic Recruiting Washington, District of Columbia, United States, 20009 Principal Investigator: Richard Elion, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.17mL

0.23mL

0.12mL

5.84mL

1.17mL

0.58mL

11.67mL

2.33mL

1.17mL

References

 

Historical Records

Categories